MCID: SML038
MIFTS: 68

Small Cell Cancer of the Lung

Categories: Respiratory diseases, Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Small Cell Cancer of the Lung

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung 57
Small Cell Lung Cancer 76 59 37 29 55 6
Sclc 57 12 59
Small Cell Carcinoma of Lung 12 73
Lung Small Cell Carcinoma 12 15
Lung Oat Cell Carcinoma 12 15
Carcinoma, Small Cell 44 73
Small Cell Neuroendocrine Carcinoma of Lung 12
Poorly Differentiated Endocrine Neoplasm 12
Oat Cell Carcinoma of Lung 12
Small-Cell Cancer of Lung 57
Small Cell Lung Carcinoma 44
Cancer, Lung, Small Cell 40
Oat Cell Carcinoma 12
Carcinoma Oat Cell 55
Sclc; Sccl 57
Sclc1 57
Sccl 57

Characteristics:

Orphanet epidemiological data:

59
small cell lung cancer
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
small cell cancer of the lung:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare respiratory diseases


External Ids:

OMIM 57 182280
Disease Ontology 12 DOID:5409 DOID:5411
NCIt 50 C4917 C3915
Orphanet 59 ORPHA70573
ICD10 via Orphanet 34 C34.9
UMLS via Orphanet 74 C0149925
MedGen 42 C0149925
KEGG 37 H00013
SNOMED-CT via HPO 69 263681008 126713003

Summaries for Small Cell Cancer of the Lung

Disease Ontology : 12 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells.

MalaCards based summary : Small Cell Cancer of the Lung, also known as small cell lung cancer, is related to gallbladder small cell carcinoma and small cell carcinoma of the bladder. An important gene associated with Small Cell Cancer of the Lung is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Small cell lung cancer and MicroRNAs in cancer. The drugs Abraxane and Alimta have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and endothelial, and related phenotypes are neoplasm of the lung and behavior/neurological

Wikipedia : 76 Small-cell carcinoma (also known as \"small-cell lung cancer\", or \"oat-cell carcinoma\") is a type of... more...

Description from OMIM: 182280

Related Diseases for Small Cell Cancer of the Lung

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma
Small Cell Lung Cancer, Adult

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
# Related Disease Score Top Affiliating Genes
1 gallbladder small cell carcinoma 33.5 CHGA ENO2 SYP
2 small cell carcinoma of the bladder 33.5 CHGA ENO2 NKX2-1 SYP
3 carcinoid syndrome 32.0 CHGA ENO2 SYP
4 lung cancer 31.8 AKT1 CCAT2 CHGA ENO2 HOTAIR HOTTIP
5 small cell carcinoma 31.2 CHGA ENO2 NKX2-1 PTEN SYP TP53
6 squamous cell carcinoma 30.8 AKT1 CCAT2 HOTAIR MALAT1 PIK3CA PTEN
7 vulvar adenocarcinoma 11.3 RB1 TP53
8 thyroid hurthle cell adenoma 11.3 PIK3CA PTEN
9 rare adenocarcinoma of the breast 11.3 AKT1 PIK3CA TP53
10 esophagus adenocarcinoma 11.3 MIR21 PIK3CA TP53
11 adult hepatocellular carcinoma 11.3 PIK3CA TP53
12 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.3 PIK3CA PTEN TP53 TP73
13 triple-receptor negative breast cancer 11.3 HOTAIR MALAT1
14 central nervous system primitive neuroectodermal neoplasm 11.3 ENO2 SYP TP53
15 ovarian clear cell carcinoma 11.3 PIK3CA PTEN TP53
16 cerebellum cancer 11.3 ENO2 SYP TP53
17 cellular ependymoma 11.3 CHGA SYP TP53
18 cerebral neuroblastoma 11.3 ENO2 SYP TP53
19 anal squamous cell carcinoma 11.3 AKT1 PIK3CA TP53
20 bladder squamous cell carcinoma 11.2 PIK3CA PTEN TP53
21 mixed type thymoma 11.2 AVP PTEN SYP
22 cerebral ventricle cancer 11.2 ENO2 SYP TP53
23 cerebrum cancer 11.2 ENO2 SYP TP53
24 supratentorial cancer 11.2 ENO2 SYP TP53
25 ureter small cell carcinoma 11.2 CHGA ENO2 SYP
26 urinary bladder small cell neuroendocrine carcinoma 11.2 CHGA ENO2 SYP
27 meningeal melanomatosis 11.2 ENO2 SYP TP53
28 esophageal neuroendocrine tumor 11.2 CHGA SYP
29 auditory system cancer 11.2 CHGA ENO2 SYP
30 malignant sertoli cell tumor 11.2 ENO2 SYP
31 glomus tumor 11.2 ENO2 SYP TP53
32 mixed cell type cancer 11.2 ENO2 SYP TP53
33 malignant spiradenoma 11.2 PIK3CA TP53
34 pleomorphic xanthoastrocytoma 11.2 CHGA SYP TP53
35 basaloid squamous cell carcinoma 11.2 ENO2 SYP TP53
36 cerebral primitive neuroectodermal tumor 11.2 ENO2 SYP TP53
37 giant cell glioblastoma 11.2 PTEN SYP TP53
38 pulmonary large cell neuroendocrine carcinoma 11.2 CHGA ENO2 SYP
39 optic nerve neoplasm 11.2 ENO2 SYP TP53
40 proteus syndrome 11.2 AKT1 PIK3CA PTEN
41 intracranial primitive neuroectodermal tumor 11.2 CHGA ENO2
42 cauda equina neoplasm 11.2 CHGA ENO2 SYP
43 medullomyoblastoma 11.2 ENO2 SYP TP53
44 pituitary adenoma 11.2 CCAT2 HOTAIR MALAT1
45 adult medulloblastoma 11.2 ENO2 SYP TP53
46 nodular ganglioneuroblastoma 11.2 CHGA ENO2 SYP
47 ovarian epithelial cancer 11.2 CCAT2 HOTAIR MALAT1 PIK3CA
48 clear cell ependymoma 11.2 ENO2 SYP TP53
49 gliosarcoma 11.2 ENO2 PTEN RB1 TP53
50 chromophobe adenoma 11.2 AVP POMC TP53

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:



Diseases related to Small Cell Cancer of the Lung

Symptoms & Phenotypes for Small Cell Cancer of the Lung

Symptoms via clinical synopsis from OMIM:

57
Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy


Clinical features from OMIM:

182280

Human phenotypes related to Small Cell Cancer of the Lung:

32
# Description HPO Frequency HPO Source Accession
1 neoplasm of the lung 32 HP:0100526

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 AKT1 AVP ENO2 NKX2-1 PIK3CA POMC
2 endocrine/exocrine gland MP:0005379 9.91 AKT1 CHGA NKX2-1 PIK3CA POMC PTEN
3 neoplasm MP:0002006 9.76 AKT1 NKX2-1 PIK3CA POMC PTEN RB1
4 nervous system MP:0003631 9.7 PIK3CA POMC PTEN RB1 SYP TP53
5 no phenotypic analysis MP:0003012 9.17 AVP CHGA NKX2-1 PIK3CA POMC RB1

Drugs & Therapeutics for Small Cell Cancer of the Lung

FDA approved drugs:

(show all 19)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
3
Avastin 18 49 BEVACIZUMAB Genentech July 2009
4
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
5
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
6
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
7
Iressa 18 49 GEFITINIB AstraZeneca May 2003
8
Neutroval 18 tbo-filgrastim Teva Pharmaceutical August 2012
9
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
10
Photofrin 18 PORFIMER SODIUM QLT January 1998
11
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
12
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996
13
Xalkori 18 49 CRIZOTINIB Pfizer August of 2011
14
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
15
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
16
Zykadia 18 49 CERITINIB Novartis April 2014
17
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015
18
Portazza 18 NECITUMUMAB Eli Lilly November 2015
19
Tagrisso 18 OSIMERTINIB MESYLATE AstraZeneca November 2015

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
4
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 942 89594
7
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
8
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
9 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Antidepressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2
16 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
17 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
18 Dopamine Agents Phase 4,Phase 3,Phase 2
19 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Central Nervous System Stimulants Phase 4,Phase 3,Phase 1,Not Applicable
25 Cholinergic Agents Phase 4,Phase 3,Phase 1,Not Applicable
26 Nicotinic Agonists Phase 4,Phase 3,Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
30
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
34
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
35
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
36
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1 4342-03-4 5351166
37
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
38
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
39
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 119413-54-6, 123948-87-8 60700
40
Dalteparin Approved Phase 3 9005-49-6
41
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 772 46507594
42
Mesna Approved, Investigational Phase 3 3375-50-6 598
43
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
44
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
45
Vinorelbine Approved, Investigational Phase 3,Phase 1,Phase 2 71486-22-1 60780 44424639
46
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
47
Enoxaparin Approved Phase 3,Phase 2 9005-49-6 772
48
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 216974-75-3
49 Amrubicin Approved, Investigational Phase 3,Phase 2,Phase 1 110267-81-7
50
Marimastat Approved, Investigational Phase 3 154039-60-8 119031

Interventional clinical trials:

(show top 50) (show all 803)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Recruiting NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
4 the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) Not yet recruiting NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
5 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4 Icotinib
6 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3 cisplatin;etoposide;cisplatin;etoposide
7 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
8 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3 cisplatin;cyclophosphamide;epirubicin hydrochloride;etoposide
9 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
10 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;paclitaxel
11 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3 carboplatin;epirubicin hydrochloride;etoposide;etoposide phosphate;ifosfamide;paclitaxel
12 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
13 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3 Carboplatin;Palifosfamide-tris;Etoposide;Carboplatin
14 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3 picoplatin
15 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3 Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
16 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
17 SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
18 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
19 A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer Completed NCT00717938 Phase 3 cisplatinum or carboplatin and e.g.etoposide.;cisplatinum or carboplatin and e.g.etoposide+enoxaparin
20 Bevacizumab in Extensive Small Cell Lung Cancer Completed NCT00930891 Phase 2, Phase 3 Standard Chemotherapy (PCDE or PE);Experimental Treatment (PCDE or PE + bevacizumab);Prerandomization Chemotherapy (PCDE or PE)
21 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
22 Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer Completed NCT01125995 Phase 3
23 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed NCT01450761 Phase 3 Etoposide;Cisplatin;Carboplatin
24 Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer Completed NCT00003011 Phase 3 marimastat;Placebo
25 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Completed NCT00119613 Phase 3 placebo;darbepoetin alfa
26 Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults Completed NCT00043927 Phase 3 topotecan/cisplatin;etoposide/cisplatin
27 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Completed NCT00143455 Phase 3 Etoposide + cisplatin;Irinotecan + cisplatin
28 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed NCT00363415 Phase 3 pemetrexed;etoposide;carboplatin
29 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3 Cisplatin + etoposide;Epirubicin + ifosfamide + etoposide
30 Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer Completed NCT00003364 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
31 Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00003299 Phase 3 cisplatin;etoposide;paclitaxel
32 Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00006352 Phase 3
33 Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission Completed NCT00005062 Phase 3
34 Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer Completed NCT00061919 Phase 3 Carboplatin, etoposide & thalidomide;Carboplatin, etoposide & placebo
35 Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed NCT00006349 Phase 3 donepezil hydrochloride
36 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3 cisplatin;etoposide;irinotecan hydrochloride
37 Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00003279 Phase 3
38 Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Completed NCT00016211 Phase 3
39 Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer Completed NCT00002822 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
40 Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer Completed NCT00003917 Phase 3 topotecan hydrochloride
41 A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
42 Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Completed NCT00320359 Phase 3 Intravenous topotecan/cisplatin;Intravenous etoposide/cisplatin
43 Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
44 A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer Completed NCT00349492 Phase 3 IP
45 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00041015 Phase 3 cisplatin;etoposide;topotecan hydrochloride
46 Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer Completed NCT00433498 Phase 3 carboplatin;cisplatin;etoposide phosphate;pravastatin sodium
47 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed NCT00660504 Phase 3 Amrubicin Hydrochloride;Etoposide-Cisplatin combined chemotherapy
48 Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide Completed NCT00290953 Phase 2, Phase 3 SR48692
49 Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Completed NCT00276276 Phase 3 topotecan
50 National Lung Screening Trial (NLST) Screening Completed NCT00047385 Phase 3

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, small cell

Genetic Tests for Small Cell Cancer of the Lung

Genetic tests related to Small Cell Cancer of the Lung:

# Genetic test Affiliating Genes
1 Small Cell Lung Cancer 29 RB1

Anatomical Context for Small Cell Cancer of the Lung

MalaCards organs/tissues related to Small Cell Cancer of the Lung:

41
Lung, Brain, Endothelial, Bone, Lymph Node, Prostate, Testes

Publications for Small Cell Cancer of the Lung

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 9984)
# Title Authors Year
1
Trends in Cardiac Mortality in Patients With Locally Advanced Non-Small Cell Lung Cancer. ( 29353659 )
2018
2
A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With <i>BRAF</i> Mutation and Expression Of PD-L1. ( 29760834 )
2018
3
MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2. ( 29510198 )
2018
4
miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer. ( 29131440 )
2018
5
Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer. ( 29374744 )
2018
6
Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. ( 28812120 )
2018
7
Coexistence of Lambert-Eaton myasthenic syndrome and autoimmune encephalitis with anti-CRMP5/CV2 and anti-GABAB receptor antibodies in small cell lung cancer: A case report. ( 29742721 )
2018
8
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. ( 29101033 )
2018
9
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. ( 29217088 )
2018
10
Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. ( 29606948 )
2018
11
[Analysis of Prognostic Factors and Clinical Characteristics for Patients with Limited Stage Small Cell Lung Cancer with Pleural Effusion]. ( 29357968 )
2018
12
Long non-coding RNA XIST promotes TGF-I^-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. ( 29339211 )
2018
13
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. ( 28913619 )
2018
14
Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer. ( 29977541 )
2018
15
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. ( 29451020 )
2018
16
Retraction: Effect of Long Non-Coding RNA LINC01116 on Biological Behaviors of Non-Small Cell Lung Cancer Cells via the Hippo Signaling Pathway. ( 29377239 )
2018
17
miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. ( 29107102 )
2018
18
Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. ( 29470986 )
2018
19
Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer. ( 29472032 )
2018
20
Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice. ( 29174086 )
2018
21
Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease. ( 29936470 )
2018
22
CD103<sup>+</sup>CD8<sup>+</sup>T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade. ( 29448979 )
2018
23
Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer. ( 29277824 )
2018
24
Effects of MALAT1 on proliferation and apo- ptosis of human non-small cell lung cancer A549 cells in vitro and tumor xenograft growth in vivo by modulating autophagy. ( 29439314 )
2018
25
miR-455-3p serves as prognostic factor and regulates the proliferation and migration of non-small cell lung cancer through targeting HOXB5. ( 29170127 )
2018
26
Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. ( 29969801 )
2018
27
Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient. ( 29981156 )
2018
28
Induction Therapies Plus Surgery Versus Exclusive Radiochemotherapy in Stage IIIA/N2 Non-Small Cell Lung Cancer (NSCLC). ( 29116951 )
2018
29
Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis. ( 29387404 )
2018
30
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer. ( 29536229 )
2018
31
Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. ( 29449529 )
2018
32
ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer. ( 29151270 )
2018
33
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib and Afatinib in Japanese Patients with Non-small Cell Lung Cancer. ( 29321093 )
2018
34
Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1I+ in non-small cell lung cancer A549 cells. ( 29971135 )
2018
35
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. ( 29106448 )
2018
36
Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis. ( 29290266 )
2018
37
Paraneoplastic striatal encephalitis and myelitis associated with anti-CV2/CRMP-5 antibodies in a patient with small cell lung cancer. ( 29777943 )
2018
38
The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III I^-tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in non-small-cell lung cancer. ( 29977535 )
2018
39
Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. ( 29216508 )
2018
40
Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. ( 29978465 )
2018
41
FPPS mediates TGF-I^1-induced non-small cell lung cancer cell invasion and the EMT process via the RhoA/Rock1 pathway. ( 29337059 )
2018
42
Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer. ( 27860390 )
2018
43
Long non-coding RNA linc01433 promotes migration and invasion in non-small cell lung cancer. ( 29532622 )
2018
44
Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry. ( 29451745 )
2018
45
Linarin inhibits radiation-induced cancer invasion by downregulating MMP-9 expression via the suppression of NF-I_B activation in human non-small-cell lung cancer A549. ( 29897257 )
2018
46
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. ( 29978725 )
2018
47
Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo. ( 29356692 )
2018
48
The prognostic impact of combined pulmonary fibrosis and emphysema in patients with clinical stage IA non-small cell lung cancer. ( 28821979 )
2018
49
Non-Small Cell Lung Cancer Drop Metastasis Causing Lumbosacral Radiculopathy. ( 29878259 )
2018
50
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. ( 29449326 )
2018

Variations for Small Cell Cancer of the Lung

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

6
(show top 50) (show all 192)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
7 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
9 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
10 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
11 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 GRCh37 Chromosome 13, 49039164: 49039164
12 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 GRCh38 Chromosome 13, 48465028: 48465028
13 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
14 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
15 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
20 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
21 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
22 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
23 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh38 Chromosome 3, 179218294: 179218294
24 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
25 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 GRCh38 Chromosome 17, 7675124: 7675124
26 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
27 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
28 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
29 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
30 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
31 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh38 Chromosome 17, 7674262: 7674262
32 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
33 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
34 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
35 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
36 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
37 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh38 Chromosome 17, 7673764: 7673764
38 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
39 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
40 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
41 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
42 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
43 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh38 Chromosome 17, 7675125: 7675125
44 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Likely pathogenic rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
45 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Likely pathogenic rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
46 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
47 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
48 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
49 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
50 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh38 Chromosome 17, 7674263: 7674263

Cosmic variations for Small Cell Cancer of the Lung:

9
(show top 50) (show all 631)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6965819 XIAP lung,NS,carcinoma,non small cell carcinoma c.833C>A p.S278* 23:123886495-123886495 26
2 COSM6959777 VTCN1 lung,NS,carcinoma,non small cell carcinoma c.505G>A p.E169K 1:117153310-117153310 26
3 COSM6964908 U2AF1 lung,NS,carcinoma,non small cell carcinoma c.140C>T p.A47V 21:43100512-43100512 26
4 COSM5010415 TSC2 lung,NS,carcinoma,non small cell carcinoma c.2647C>T p.Q883* 16:2076075-2076075 26
5 COSM138991 TSC2 lung,NS,carcinoma,non small cell carcinoma c.5131G>A p.V1711M 16:2088110-2088110 26
6 COSM3591180 TP63 lung,NS,carcinoma,non small cell carcinoma c.797G>A p.R266Q 3:189866712-189866712 26
7 COSM10660 TP53 lung,NS,carcinoma,non small cell carcinoma c.818G>A p.R273H 17:7673802-7673802 26
8 COSM10991 TP53 lung,NS,carcinoma,non small cell carcinoma c.396G>T p.K132N 17:7675216-7675216 26
9 COSM43896 TP53 lung,NS,carcinoma,non small cell carcinoma c.818G>C p.R273P 17:7673802-7673802 26
10 COSM43959 TP53 lung,NS,carcinoma,non small cell carcinoma c.790C>A p.L264I 17:7673830-7673830 26
11 COSM43911 TP53 lung,NS,carcinoma,non small cell carcinoma c.451C>A p.P151T 17:7675161-7675161 26
12 COSM10905 TP53 lung,NS,carcinoma,non small cell carcinoma c.451C>T p.P151S 17:7675161-7675161 26
13 COSM43726 TP53 lung,NS,carcinoma,non small cell carcinoma c.727A>T p.M243L 17:7674236-7674236 26
14 COSM10714 TP53 lung,NS,carcinoma,non small cell carcinoma c.473G>T p.R158L 17:7675139-7675139 26
15 COSM10656 TP53 lung,NS,carcinoma,non small cell carcinoma c.742C>T p.R248W 17:7674221-7674221 26
16 COSM11081 TP53 lung,NS,carcinoma,non small cell carcinoma c.733G>T p.G245C 17:7674230-7674230 26
17 COSM10709 TP53 lung,NS,carcinoma,non small cell carcinoma c.722C>G p.S241C 17:7674241-7674241 26
18 COSM10758 TP53 lung,NS,carcinoma,non small cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 26
19 COSM44769 TP53 lung,NS,carcinoma,non small cell carcinoma c.755T>C p.L252P 17:7674208-7674208 26
20 COSM43650 TP53 lung,NS,carcinoma,non small cell carcinoma c.638G>T p.R213L 17:7674893-7674893 26
21 COSM45102 TP53 lung,NS,carcinoma,non small cell carcinoma c.423C>T p.C141C 17:7675189-7675189 26
22 COSM43687 TP53 lung,NS,carcinoma,non small cell carcinoma c.641A>G p.H214R 17:7674890-7674890 26
23 COSM43871 TP53 lung,NS,carcinoma,non small cell carcinoma c.746G>T p.R249M 17:7674217-7674217 26
24 COSM11148 TP53 lung,NS,carcinoma,non small cell carcinoma c.476C>T p.A159V 17:7675136-7675136 26
25 COSM43714 TP53 lung,NS,carcinoma,non small cell carcinoma c.836G>A p.G279E 17:7673784-7673784 26
26 COSM6815 TP53 lung,NS,carcinoma,non small cell carcinoma c.461G>T p.G154V 17:7675151-7675151 26
27 COSM43708 TP53 lung,NS,carcinoma,non small cell carcinoma c.422G>A p.C141Y 17:7675190-7675190 26
28 COSM10663 TP53 lung,NS,carcinoma,non small cell carcinoma c.916C>T p.R306* 17:7673704-7673704 26
29 COSM10777 TP53 lung,NS,carcinoma,non small cell carcinoma c.715A>G p.N239D 17:7674248-7674248 26
30 COSM10992 TP53 lung,NS,carcinoma,non small cell carcinoma c.844C>G p.R282G 17:7673776-7673776 26
31 COSM11564 TP53 lung,NS,carcinoma,non small cell carcinoma c.742C>G p.R248G 17:7674221-7674221 26
32 COSM11196 TP53 lung,NS,carcinoma,non small cell carcinoma c.734G>T p.G245V 17:7674229-7674229 26
33 COSM45115 TP53 lung,NS,carcinoma,non small cell carcinoma c.640C>G p.H214D 17:7674891-7674891 26
34 COSM44054 TP53 lung,NS,carcinoma,non small cell carcinoma c.754C>T p.L252F 17:7674209-7674209 26
35 COSM44512 TP53 lung,NS,carcinoma,non small cell carcinoma c.740A>G p.N247S 17:7674223-7674223 26
36 COSM10662 TP53 lung,NS,carcinoma,non small cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 26
37 COSM10645 TP53 lung,NS,carcinoma,non small cell carcinoma c.527G>T p.C176F 17:7675085-7675085 26
38 COSM45649 TP53 lung,NS,carcinoma,non small cell carcinoma c.854A>G p.E285G 17:7673766-7673766 26
39 COSM44801 TP53 lung,NS,carcinoma,non small cell carcinoma c.503A>T p.H168L 17:7675109-7675109 26
40 COSM10749 TP53 lung,NS,carcinoma,non small cell carcinoma c.830G>T p.C277F 17:7673790-7673790 26
41 COSM46344 TP53 lung,NS,carcinoma,non small cell carcinoma c.341T>A p.L114* 17:7676028-7676028 26
42 COSM43695 TP53 lung,NS,carcinoma,non small cell carcinoma c.748C>T p.P250S 17:7674215-7674215 26
43 COSM45647 TP53 lung,NS,carcinoma,non small cell carcinoma c.760A>T p.I254F 17:7674203-7674203 26
44 COSM10889 TP53 lung,NS,carcinoma,non small cell carcinoma c.536A>G p.H179R 17:7675076-7675076 26
45 COSM10779 TP53 lung,NS,carcinoma,non small cell carcinoma c.818G>T p.R273L 17:7673802-7673802 26
46 COSM43606 TP53 lung,NS,carcinoma,non small cell carcinoma c.734G>A p.G245D 17:7674229-7674229 26
47 COSM44198 TP53 lung,NS,carcinoma,non small cell carcinoma c.653T>G p.V218G 17:7674878-7674878 26
48 COSM44610 TP53 lung,NS,carcinoma,non small cell carcinoma c.97-2A>T p.? 17:7676274-7676274 26
49 COSM10672 TP53 lung,NS,carcinoma,non small cell carcinoma c.577C>T p.H193Y 17:7674954-7674954 26
50 COSM18657 TP53 lung,NS,carcinoma,non small cell carcinoma c.560-2A>G p.? 17:7674973-7674973 26

Copy number variations for Small Cell Cancer of the Lung from CNVD:

7 (show top 50) (show all 515)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and in dels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and in dels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and in dels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and in dels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and in dels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rea rrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and in dels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rea rrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and in dels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rea rrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and in dels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rea rrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rea rrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and in dels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rea rrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rea rrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and in dels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rea rrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and in dels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rea rrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and in dels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rea rrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and in dels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rea rrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and in dels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rea rrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and in dels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and in dels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and in dels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and in dels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and in dels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and in dels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and in dels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and in dels small cell lung cancer

Expression for Small Cell Cancer of the Lung

Search GEO for disease gene expression data for Small Cell Cancer of the Lung.

Pathways for Small Cell Cancer of the Lung

Pathways related to Small Cell Cancer of the Lung according to KEGG:

37
# Name Kegg Source Accession
1 Small cell lung cancer hsa05222
2 MicroRNAs in cancer hsa05206

Pathways related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1 12.78 AKT1 PIK3CA PTEN RB1 TP53
2
Show member pathways
12.7 AKT1 PIK3CA PTEN RB1 TP53
3
Show member pathways
12.69 AKT1 PIK3CA PTEN RB1 TP53
4
Show member pathways
12.61 AKT1 PIK3CA PTEN TP53 TP73
5 12.48 AVP ENO2 NKX2-1 POMC SYP
6
Show member pathways
12.45 AKT1 PIK3CA PTEN RB1 TP53
7 12.36 AKT1 PIK3CA RB1 TP53
8
Show member pathways
12.31 PTEN RB1 TP53 TP73
9 12.2 AKT1 PIK3CA RB1 TP53
10 12.2 AKT1 MIR21 PIK3CA TP53
11
Show member pathways
12.15 AKT1 PTEN RB1 TP53
13 12.07 AKT1 PIK3CA PTEN TP53
14 12.05 AKT1 PTEN RB1 TP53
15 11.95 PTEN RB1 TP53 TP73
16 11.92 AKT1 PIK3CA PTEN RB1 TP53
17
Show member pathways
11.91 AKT1 PIK3CA PTEN TP53
18 11.87 AKT1 PIK3CA PTEN TP53
19 11.81 AKT1 PIK3CA PTEN
20 11.8 AKT1 PTEN RB1
21 11.8 AKT1 PTEN RB1 TP53
22 11.75 AKT1 PTEN TP53
23 11.73 AKT1 POMC TP53
24 11.67 AKT1 PIK3CA TP53
25 11.62 AKT1 PIK3CA RB1
26
Show member pathways
11.6 AKT1 PIK3CA TP53
27 11.52 AKT1 PIK3CA PTEN TP53
28 11.48 AKT1 PIK3CA PTEN
29 11.48 AKT1 PIK3CA PTEN TP53
30 11.41 AKT1 PIK3CA PTEN TP53 TP73
31 11.29 AKT1 PIK3CA PTEN TP53
32 11.13 AKT1 PIK3CA PTEN
33 11.12 AKT1 PTEN RB1 TP53
34 10.99 AKT1 PIK3CA PTEN RB1 TP53
35 10.73 HOTAIR TP53

GO Terms for Small Cell Cancer of the Lung

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.85 AKT1 AVP PTEN RB1 TP53 TP73
2 locomotory behavior GO:0007626 9.67 AVP NKX2-1 PTEN
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.65 AKT1 AVP PIK3CA
4 positive regulation of apoptotic process GO:0043065 9.65 AKT1 MIR21 PTEN TP53 TP73
5 negative regulation of macroautophagy GO:0016242 9.52 AKT1 PIK3CA
6 maternal behavior GO:0042711 9.51 AVP PTEN
7 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.5 MIR21 PTEN RB1
8 mitotic G1 DNA damage checkpoint GO:0031571 9.46 TP53 TP73
9 anoikis GO:0043276 9.43 AKT1 PIK3CA
10 negative regulation of cell size GO:0045792 9.4 AKT1 PTEN
11 protein kinase B signaling GO:0043491 9.33 AKT1 PIK3CA PTEN
12 positive regulation of gene expression GO:0010628 9.1 AKT1 AVP MIR21 NKX2-1 PTEN TP53
13 cellular response to decreased oxygen levels GO:0036294 8.96 AKT1 PTEN

Molecular functions related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.02 AKT1 NKX2-1 PTEN RB1 TP53
2 RNA polymerase II regulatory region DNA binding GO:0001012 8.96 NKX2-1 RB1

Sources for Small Cell Cancer of the Lung

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....